表紙
市場調查報告書

癌症原遺傳基因酪胺酸蛋白激酶Src:開發中產品分析

Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 516026
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
癌症原遺傳基因酪胺酸蛋白激酶Src:開發中產品分析 Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 98 Pages
簡介

本報告提供癌症原遺傳基因酪胺酸蛋白激酶Src為標的之治療藥的開發相關資訊,開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

癌症原遺傳基因酪胺酸蛋白激酶Src;概要

癌症原遺傳基因酪胺酸蛋白激酶Src;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀
  • 企業開發中的產品
  • 在大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Asana BioSciences LLC
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Onconova Therapeutics Inc
  • Oribase Pharma
  • TopiVert Ltd

藥物簡介

暫停中的產品

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2265TDB

Summary

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2020, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 1, 4 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ulcerative Colitis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Lymphangioleiomyomatosis, Medullary Thyroid Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alcohol Addiction, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Angiosarcoma, Bladder Cancer, Breast Cancer, Bronchiolitis Obliterans, Cancer Pain, Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Friedreich Ataxia, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease), Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Keratoconjunctivitis Sicca (Dry Eye), Lewy Body Dementia, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Parkinson's Disease, Peritoneal Cancer, Pneumoconiosis, Psychosis, Refractory Acute Myeloid Leukemia, Salivary Gland Cancer, Squamous Non-Small Cell Lung Cancer and Uterine Cancer.

Furthermore, this report also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
  • The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Fratagene Therapeutics Srl
  • Lead Discovery Center GmbH
  • Onconova Therapeutics Inc
  • Prous Institute for Biomedical Research SA
  • TopiVert Ltd
  • Turning Point Therapeutics Inc
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
  • bosutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ilorasertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JRP-890 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nintedanib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Ofev - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ON-150030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • repotrectinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • saracatinib difumarate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Si-306 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit SRC for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TOP-1210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TOP-1288 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TOP-1630 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TOP-1890 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPX-0022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPX-0046 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 13, 2020: Clinical Trial will evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
  • Nov 28, 2019: Health Canada approves Boehringer's Ofev to slow SSc-ILD
  • Nov 19, 2019: New advances in the treatment of advanced lung cancer
  • Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
  • Nov 11, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of TPX-0046, a novel RET/SRC inhibitor
  • Nov 07, 2019: New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
  • Oct 11, 2019: Boehringer's nintedanib secures breakthrough status in US for ILDs
  • Oct 10, 2019: FDA grants Ofev breakthrough therapy designation for chronic fibrosing ILDs with a progressive phenotype
  • Oct 09, 2019: New data showed OFEV (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
  • Oct 01, 2019: Boehringer Ingelheim announces nintedanib trial met its primary endpoint
  • Sep 30, 2019: Nintedanib slows progression for broad range of scarring Lung Diseases
  • Sep 30, 2019: INBUILD meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases
  • Sep 30, 2019: Turning Point Therapeutics announces FDA clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor
  • Sep 10, 2019: FDA approves Boehringer's Ofev for rare lung disease
  • Sep 03, 2019: Turning Point Therapeutics announces updated preclinical Data for TPX-0046, a novel RET/SRC Inhibitor
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AbbVie Inc, H1 2020
  • Pipeline by AstraZeneca Plc, H1 2020
  • Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Pipeline by Fratagene Therapeutics Srl, H1 2020
  • Pipeline by Lead Discovery Center GmbH, H1 2020
  • Pipeline by Onconova Therapeutics Inc, H1 2020
  • Pipeline by Prous Institute for Biomedical Research SA, H1 2020
  • Pipeline by TopiVert Ltd, H1 2020
  • Pipeline by Turning Point Therapeutics Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020